A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy
Tóm tắt
Từ khóa
Tài liệu tham khảo
1. Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 51: 743-750, 2011 (in Japanese, Abstract in English).
2. Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med 49: 1357-1363, 2010.
3. Kanzaki M, Zhang YQ, Mashima H, Shibata H, Kojima I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-1. Nat Cell Biol 1: 165-170, 1999.
4. Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2<sup>+</sup>-permeable growth factor-regulated channel. J Cell Biol 161: 957-967, 2003.
5. Iwata Y, Ohtake H, Suzuki O, Matsuda J, Komamura K, Wakabayashi S. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res 99: 760-768, 2013.
6. Iwata Y, Katanosaka Y, Shijun Z, et al. Protective effects of Ca2<sup>+</sup> handling drugs against abnormal Ca2<sup>+</sup> homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 70: 740-751, 2005.
7. Iwata Y, Katanosaka Y, Arai Y, Shigekawa M, Wakabayashi S. Dominant-negative inhibition of Ca2<sup>+</sup> influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet 18: 824-834, 2009.
8. Zanou N, Iwata Y, Schakman O, Lebacq J, Wakabayashi S, Gailly P. Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions. FEBS Lett 583: 3600-3604, 2009.
9. Kato K, Tamai H, Hayakawa H, et al. Clinical evaluation of tranilast on restenosis after percutaneous transluminal coronary angiopathy (PTCA) -a double-blind placebo-controlled comparative study-. Rinshoiyaku 12: 65-85, 1996 (in Japanese, Abstract in English).
10. Itagane H, Haji K, Kodama K, et al. Effects of tranilast on restenosis after percutaneous transluminal coronary angiopathy -a multi center phase III open trial-. Shinnyaku to Rinsho 45: 267-280, 1996 (in Japanese, Abstract in English).
11. Takekoshi N, Kanemitsu S, Kitayama M, et al. Clinical evaluation of tranilast in the prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) -a phase III multicenter open trial-. Kiso to Rinsho 30: 593-609, 1996 (in Japanese, Abstract in English).
12. Nagino K, Nomura O, Takii Y, et al. Ultrasensitive DNA chip: gene expression profile analysis without RNA amplification. J Biochem 139: 697-703, 2006.
13. Cacchiarelli D, Legnini I, Martone J, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 3: 258-265, 2011.
14. Demachi J, Kagaya Y, Watanabe J, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idopathic dilated cardiomyopathy. Neurmuscul Disord 14: 732-739, 2004.
15. Adachi K, Kawai H, Kimura C, et al. Estimation of the prognosis of patients with Duchenne muscular dystrophy and cardiac failure on their plasma level of natriuretic peptide. Shinkeinaika 1998 49: 532-536, 1998 (in Japanese, Abstract in English).
16. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119: 2772-2786, 2009.
17. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124: 1537-1547, 2011.
18. Dickinson BA, Semus HM, Montgomery RL, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 15: 650-659, 2013.
19. Barsanti C, Trivella MG, D'Aurizio R, et al. Differential regulation of microRNAs in end-stage failing hearts is associated with left ventricular assist device unloading. Biomed Res Int 2015 (Epub ahead of print).